Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016
Investigation of gram positive antibiotics as aerosol administration (cubicin, vancomycin, zyvoxid) Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Comparative evaluation of timing of antibiotic intravenous-to-oral switch in pneumonia Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Antibiotics to treat Community-acquired Lower Respiratory Tract Infections: mechanism of action, spectrum, epidemiology resistance. Source: Value-Dx event 2019: VALUE-Dx kick off meeting and course Year: 2019
Safety of intravenous amikacin in the treatment of pulmonary non-tuberculous mycobacterial disease Source: Annual Congress 2013 –Non-tuberculous mycobacteria: clinical management Year: 2013
Colistin therapy for nosocomial pneumonia and nephrotoxicity Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013
Modification of empirical antibiotic therapy in community acquired pneumonia Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014
Effects of ulinastatin in treatment of invasive candidiasis Source: Annual Congress 2013 –Infection, sepsis and outcomes in ICU Year: 2013
Relationship between the use of inhaled steroids and early outcomes in community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016
Pathogen profile of lung infections in systemic autoimmune diseases Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections Year: 2014
Effect of long term azithromycin on exacerbations in non CF bronchiectasis Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Population pharmacokinetics and pharmacodynamics analysis of vancomycin in patients with severe lower respiratory tract gram-positive infections Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Fluticasone propionate alters the respiratory tract microbiota and has dose-related effects on anti-bacterial host defence Source: International Congress 2016 – Translational research in respiratory infections Year: 2016
Outcomes of antioxidant administration in experimentally induced pneumonia Source: Annual Congress 2013 –The multiple faces of stress in lung injury Year: 2013
High prevalence of resistant bacterial infections in patients with tracheostomy due to neuromuscular disease (NMD) Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014
Frequency of multidrug resistant pathogens in healthcare associated pneumonia Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections Year: 2014
Etiological features of low respiratory tract infections in the department of pulmonology. Update 2013 Source: International Congress 2014 – Different interesting issues in respiratory infections: 1 Year: 2014
Decametoxine efficiency in the treatment of infectious exacerbation of asthma Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
Prevention of paediatric respiratory tract infections: emphasis on the role of OM-85 Source: Eur Respir Rev 2005; 14: 74-77 Year: 2005
Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections Year: 2014